Report Overview

The market research report is created with a compilation of analytical research based on historic records, current statistics, and future predictions. The report contains details on the leading players operating in the Liraglutide market including various factors related to and dependent influencing the market growth.

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The total amount of Patents about Liraglutide are 1871, among those Patents, 44%is about application, 26%is about Combination therapy, and 12%is about Preparation method.
In these patents, accounting for Europe is the largest, followed by North America, and finally Asia.
The application of Liraglutide
Liraglutide for the treatment of type 2 diabetes mellitus
Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in Type 2 diabetes: the management of type 2 diabetes
Liraglutide 1.2 mg daily in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended as an option for the treatment of people with type 2 diabetes, only if the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.
Liraglutide 1.8 mg daily is not recommended for the treatment of people with type 2 diabetes.
The Committee concluded that the evidence provided was not robust enough to allow it to recommend liraglutide as a cost-effective alternative to either thiazolidinediones or DPP-4 inhibitors as a triple therapy regimen, however it believes liraglutide is a cost-effective treatment option relative to exenatide.

Taking into account the lack of clinical trial evidence showing a significant benefit from increasing the liraglutide dose from 1.2 mg to 1.8 mg, the widely varying ICERs and the uncertainty in the economic analysis, the Committee was unable to recommend liraglutide 1.8 mg for the treatment of type 2 diabetes.
The Committee concluded that people with type 2 diabetes currently receiving liraglutide who do not meet the criteria specified in section 1.1 or 1.3, or who are receiving liraglutide 1.8 mg, should have the option to continue their current treatment until they and their clinicians consider it appropriate to stop.

The global Liraglutide market is valued at xx million US$ in 2020 and will reach xx million US$ by the end of 2030, growing at a CAGR of xx% during 2023-2030. The objectives of this study are to define, segment, and project the size of the Liraglutide market based on company, product type, end user and key regions.

This report studies the global market size of Liraglutide in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Liraglutide in these regions.
This research report categorizes the global Liraglutide market by top players/brands, region, type and end user. This report also studies the global Liraglutide market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The report is prepared using analytical methods such as SWOT (strengths, weaknesses, opportunities, and threats)) analysis, PESTEL Analysis, Porter\'s Five Force Analysis, and value chain analysis. These methods provide a clear view of the market structure and analyze competition at a global level. They also provide detailed information on each segment in the global Liraglutide market.

The aim of the report is to interpret the market sizes of various segments and countries for the forecast period. The study includes the qualitative and quantitative analysis of the market. The report analyses the Liraglutide market on a regional and global level with a deep analysis of macro-and micro-economic factors impacting the growth of the market. This report also includes market information related to the latest industry trends, market developments, and analysis of products and end users contributing to market growth. An in-depth study of the current market scenario, major driving factors, and restraining factors for the market are also included in the report.

The Liraglutide market report includes information related to market segmentation, market size and revenue forecasts, and regional forecasts along with information about the leading market players operating in the market, company revenue shares and, their recent developments. The market is classified regionally on country-level into North America, Europe, Asia Pacific, the Middle East and Africa, and South America.

Scope of the Liraglutide Market:
The major competitors working in the market are:
, HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide, AmbioPharm

Market by Order Type

Pills
Liquid
Market size by End User
Hospital
Drug Store

Regions Covered in the Report are:

• North America


• Europe


• Asia Pacific


• Middle East & Africa


• Rest of the World

The information about the Liraglutide market is obtained from several sources such as company websites, journals, annual reports, which were then assessed and verified by the industry experts. The information is represented in the form of diagrams, charts, pie charts, and infographics, which helps in a better understanding of the market.

Objectives of Liraglutide Market Report:

• To analyze the factors driving the market growth including supply chain analysis, price analysis along with other analytical methods


• To provide an in-depth analysis of the Liraglutide market with information on various segment and sub-segments


• To provide a regional analysis and global analysis for the Liraglutide market size and their forecasts


• To provide strategic profiles of the key players operating in the Liraglutide market, their key competencies, and market competition


• To provide a competitive scenario about the key factors driving, restraining, and challenging the market growth.


• The impact of COVID-19 pandemic on the Liraglutide market

Target Audiences for Liraglutide Market:

• Investors


• Investment Bankers


• Key Consulting Companies and Advisors


• Venture Capitalists


• Large, Medium-sized, and Small enterprises

Customization:
We also provide customized reports according to customer\'s specific requirements. We also provide customization for regional and country-level reports individually.

To check our Table of Contents, please mail us at: sales@marketresearchupdate.com

Research Methodology

The Market Research Update offers technology-driven solutions and its full integration in the research process to be skilled at every step. We use diverse assets to produce the best results for our clients. The success of a research project is completely reliant on the research process adopted by the company. Market Research Update assists its clients to recognize opportunities by examining the global market and offering economic insights. We are proud of our extensive coverage that encompasses the understanding of numerous major industry domains.

Market Research Update provide consistency in our research report, also we provide on the part of the analysis of forecast across a gamut of coverage geographies and coverage. The research teams carry out primary and secondary research to implement and design the data collection procedure. The research team then analyzes data about the latest trends and major issues in reference to each industry and country. This helps to determine the anticipated market-related procedures in the future. The company offers technology-driven solutions and its full incorporation in the research method to be skilled at each step.

The Company's Research Process Has the Following Advantages:

1. Information Procurement

The step comprises the procurement of market-related information or data via different methodologies & sources.

2. Information Investigation

This step comprises the mapping and investigation of all the information procured from the earlier step. It also includes the analysis of data differences observed across numerous data sources.

3. Highly Authentic Source

We offer highly authentic information from numerous sources. To fulfills the client’s requirement.

4. Market Formulation

This step entails the placement of data points at suitable market spaces in an effort to assume possible conclusions. Analyst viewpoint and subject matter specialist based examining the form of market sizing also plays an essential role in this step.

5. Validation & Publishing of Information

Validation is a significant step in the procedure. Validation via an intricately designed procedure assists us to conclude data-points to be used for final calculations.